Venclexta and Feeding disorder - a phase IV clinical study of FDA data

Summary:

Feeding disorder is reported as a side effect among people who take Venclexta (venetoclax), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Ondansetron, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Feeding disorder when taking Venclexta. It is created by eHealthMe based on reports of 31,417 people who have side effects when taking Venclexta from the FDA, and is updated regularly.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

What is Feeding disorder?

Feeding disorder (when children refuse to eat certain food groups) is found to be associated with 1,009 drugs and 904 conditions by eHealthMe. Check the latest studies of Feeding disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

31,417 people reported to have side effects when taking Venclexta.
Among them, 40 people (0.13%) have Feeding disorder.

Among these 40 people:

How long have people been on Venclexta when they have Feeding disorder? *

What is the gender of people who have Feeding disorder when taking Venclexta? *

female: 52.63 %
male: 47.37 %

What is the age of people who have Feeding disorder when taking Venclexta? *

What are other drugs people take besides Venclexta? *

What are other side effects people have besides Feeding disorder? *

Weakness: 18 people, 45.00%
White Blood Cell Count Decreased: 12 people, 30.00%
Fatigue (feeling of tiredness): 11 people, 27.50%
Thrombocytopenia (decrease of platelets in blood): 11 people, 27.50%
Weight Decreased: 9 people, 22.50%
Malaise (a feeling of general discomfort or uneasiness): 9 people, 22.50%
Pneumonia: 8 people, 20.00%
Nausea (feeling of having an urge to vomit): 8 people, 20.00%
Haemoglobin Decreased: 7 people, 17.50%
Memory Loss: 6 people, 15.00%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 19 people, 47.50%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 17 people, 42.50%
High Blood Pressure: 6 people, 15.00%
Lymphoma (cancer that begins in immune system cells): 4 people, 10.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 10.00%
High Blood Cholesterol: 2 people, 5.00%
Pain: 2 people, 5.00%
Arrhythmias (irregular heartbeat): 2 people, 5.00%
Depression: 2 people, 5.00%
Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Venclexta and have Feeding disorder?

- Check whether Feeding disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Venclexta:

Venclexta (31,425 reports)

Feeding disorder treatments and more:

Feeding disorder (19,118 reports)

Browse all side effects of Venclexta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Feeding disorder:

Feeding disorder (1,009 drugs)

Browse all the conditions that are associated with Feeding disorder:

Feeding disorder (904 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on venetoclax (the active ingredients of Venclexta) and Venclexta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.